RECURRENT ASTROCYTOMA, IDH-MUTANT, GRADE 3
Clinical trials for RECURRENT ASTROCYTOMA, IDH-MUTANT, GRADE 3 explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ASTROCYTOMA, IDH-MUTANT, GRADE 3 trials appear
Sign up with your email to follow new studies for RECURRENT ASTROCYTOMA, IDH-MUTANT, GRADE 3, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug triapine paired with radiation targets recurrent brain cancers
Disease control Recruiting nowThis early-phase trial tests the safety and best dose of the drug triapine when given together with radiation therapy for people whose glioblastoma or astrocytoma has come back. Triapine works by blocking enzymes that cancer cells need to grow, while radiation kills cancer cells …
Matched conditions: RECURRENT ASTROCYTOMA, IDH-MUTANT, GRADE 3
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Gene-Edited immune cells take on aggressive brain tumors
Disease control Recruiting nowThis phase 1 trial tests a new type of immunotherapy for people with recurrent or progressive high-grade gliomas, including glioblastoma. The treatment uses the patient's own T cells, which are genetically modified in the lab to target a protein called IL13Rα2 found on tumor cell…
Matched conditions: RECURRENT ASTROCYTOMA, IDH-MUTANT, GRADE 3
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC